These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 14648032)

  • 1. A randomized multicenter open label phase II study to determine the safety and efficacy of induction therapy with imatinib (Glivec, formerly STI571) in comparison with standard induction chemotherapy in elderly (>55 years) patients with Philadelphia chromosome-positive (Ph+/BCR-ABL+) acute lymphoblastic leukemia (ALL) (CSTI571ADE 10).
    Wassmann B; Gökbuget N; Scheuring UJ; Binckebanck A; Reutzel R; Gschaidmeier H; Hoelzer D; Ottmann OG;
    Ann Hematol; 2003 Nov; 82(11):716-20. PubMed ID: 14648032
    [No Abstract]   [Full Text] [Related]  

  • 2. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
    Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
    Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.
    Potenza L; Luppi M; Riva G; Marasca R; Martinelli S; Torelli G
    Haematologica; 2005 Sep; 90(9):1275-7. PubMed ID: 16154854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
    Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Rios MB; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Verstovsek S; Wierda W; Keating M; Talpaz M
    Cancer; 2003 Dec; 98(12):2636-42. PubMed ID: 14669283
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of elderly patients with acute lymphoblastic leukemia--evidence for a benefit of imatinib in BCR-ABL positive patients.
    Brandwein JM; Gupta V; Wells RA; Schuh AC; Schimmer AD; Lipton JH; Messner HA; Yi QL; Chun K; Kamel-Reid S; Minden MD
    Leuk Res; 2005 Dec; 29(12):1381-6. PubMed ID: 15927253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib alone and in combination for chronic myeloid leukemia.
    Druker BJ
    Semin Hematol; 2003 Jan; 40(1):50-8. PubMed ID: 12563611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favorable outcome with STI571 (imatinib mesylate) and allogeneic stem cell transplantation in a case of Ph+ chemorefractory acute lymphocytic leukaemia.
    Wernstedt P; Brune M; Andersson PO; Gustavsson B; Stockelberg D; Wadenvik H
    Bone Marrow Transplant; 2002 Dec; 30(12):971-3. PubMed ID: 12476293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up.
    Lahaye T; Riehm B; Berger U; Paschka P; Müller MC; Kreil S; Merx K; Schwindel U; Schoch C; Hehlmann R; Hochhaus A
    Cancer; 2005 Apr; 103(8):1659-69. PubMed ID: 15747376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CML clonal evolution with resistance to single agent imatinib therapy.
    Swords R; Quinn J; Fay M; O'Donnell R; Goldman J; Murphy PT
    Clin Lab Haematol; 2005 Oct; 27(5):347-9. PubMed ID: 16178920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood.
    Kolb EA; Pan Q; Ladanyi M; Steinherz PG
    Cancer; 2003 Dec; 98(12):2643-50. PubMed ID: 14669284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current use of imatinib in the treatment of chronic myeloid leukemia.
    O'Dwyer M
    Haematologica; 2003 Mar; 88(3):241-4. PubMed ID: 12651257
    [No Abstract]   [Full Text] [Related]  

  • 12. Imatinib achieved complete cytogenetic response in a CML patient received 32-year indirubin and its derivative treatment.
    Chen F; Li L; Ma D; Yan S; Sun J; Zhang M; Ji C; Hou M
    Leuk Res; 2010 Feb; 34(2):e75-7. PubMed ID: 19773083
    [No Abstract]   [Full Text] [Related]  

  • 13. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
    Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
    Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.
    Roche-Lestienne C; Darré S; Laï JL; Facon T; Guilhot J; Preudhomme C
    Haematologica; 2005 Jan; 90(1):131-3. PubMed ID: 15642682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imatinib for chronic myeloid leukemia: the impact of its effectiveness and long-term side effects.
    Smith BD
    J Natl Cancer Inst; 2011 Apr; 103(7):527-9. PubMed ID: 21422404
    [No Abstract]   [Full Text] [Related]  

  • 16. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
    Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib.
    Marin D; Kaeda JS; Andreasson C; Saunders SM; Bua M; Olavarria E; Goldman JM; Apperley JF
    Cancer; 2005 May; 103(9):1850-5. PubMed ID: 15786422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful interim therapy with imatinib prior to allogeneic stem cell transplantation in Philadelphia chromosome-positive acute myeloid leukemia.
    Cho BS; Kim HJ; Lee S; Eom KS; Min WS; Lee JW; Kim CC
    Eur J Haematol; 2007 Aug; 79(2):170-3. PubMed ID: 17608710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complete molecular remission in a patient with Philadelphia-chromosome positive acute myeloid leukemia after conventional therapy and imatinib.
    Jentsch-Ullrich K; Pelz AF; Braun H; Koenigsmann M; Mohren M; Wieacker P; Franke A
    Haematologica; 2004 May; 89(5):ECR15. PubMed ID: 15136244
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy.
    Lange T; Bumm T; Otto S; Al-Ali HK; Kovacs I; Krug D; Köhler T; Krahl R; Niederwieser D; Deininger MW
    Haematologica; 2004 Jan; 89(1):49-57. PubMed ID: 14754606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.